12-month results reinforce versatility and durability for the treatment of paroxysmal and persistent AFib with the first-of-its-kind pulsed field ablation, radiofrequency, and high density mapping Sphere-9™ Catheter Medtronic today announced the 12-month findings that supported the Affera™ Mapping and Ablation System CE Mark, demonstrating that the Sphere-9™ Catheter can successfully […]
Tag: Medtronic
Medtronic Announces Pricing of $2.0 Billion of Senior Notes
DUBLIN, March 23, 2023 /PRNewswire/ — Medtronic plc (the “Company”) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering (the “Offering”) of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000,000 principal amount of 4.50% senior notes due 2033 (collectively, the “Notes”). All of Medtronic Luxco’s obligations […]
Medtronic receives CE Mark approval for Affera™ Mapping and Ablation System to treat atrial arrhythmias
First of its kind, all-in-one Sphere-9™ Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform DUBLIN, March 15, 2023 /PRNewswire/ — Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ […]
Medtronic Evolut™ TAVR platform shows excellent valve performance and durability in low-risk aortic stenosis patients
ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years Medtronic today announced three-year data from the Evolut Low Risk Trial, demonstrating the Medtronic EvolutTM transcatheter aortic valve replacement (TAVR) System had numerically better clinical outcomes and significantly better hemodynamic valve performance than […]
Medtronic PulseSelect PFA System demonstrates impressive results in landmark PULSED AF global IDE trial
ACC.23/WCC late-breaking data: PULSED AF, one of the most rigorously executed PFA clinical studies to date, exceeds safety and efficacy performance goals in the treatment of paroxysmal and persistent atrial fibrillation DUBLIN and NEW ORLEANS, March 6, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field […]
Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2023
DUBLIN, March 2, 2023 /PRNewswire/ — The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May […]
Medtronic reports third quarter fiscal 2023 financial results
Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN, Feb. 21, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights Revenue of $7.7 billion was flat as reported and increased 4.1% organic, […]
Medtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms
EV-ICD defibrillation lead placed outside of heart and veins, preserving vasculature DUBLIN, Feb. 17, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden […]
Medtronic LINQ Insertable Cardiac Monitor detects 10 times more atrial fibrillation in ischemic stroke patients at three years compared to standard of care
ISC23: Late-breaking results from STROKE AF study reinforce importance of long-term continuous cardiac monitoring in ischemic stroke patients DUBLIN and DALLAS, Feb. 8, 2023 /PRNewswire/ — Medtronic (NYSE: MDT) today announced late-breaking clinical data from the STROKE AF clinical study, which showed large and small vessel disease stroke patients had a 10-fold increase in AF […]
Acutus Medical Achieves EU MDR Submission Milestone in Sale of Left-Heart Access Portfolio to Medtronic
CARLSBAD, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that the Company has achieved the second milestone under the asset purchase agreement with Medtronic of […]